scholarly journals Principles of selecting therapy for patients with mild asthma. RAACI and RRO agreed recommendations

2017 ◽  
Vol 14 (3) ◽  
pp. 55-63
Author(s):  
S N Avdeev ◽  
Z R Aysanov ◽  
V V Arkhipov ◽  
A S Belevskiy ◽  
A A Viesel ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Medical Care ◽  
Disease Control ◽  
Therapeutic Options ◽  
Mild Asthma ◽  
Asthma Treatment ◽  
Controlled Clinical Trials ◽  
The Creation ◽  
Rating Scheme ◽  
Selection Of

The recommendations represent the rating scheme of the assessment and selection of therapy for patients with mild asthma. The variety of therapeutic options for the treatment of easy asthma can provide the achievement of the disease control, or if it is impossible to create a good continuity with the next steps of therapy. Fixed IGX/ KDBA and IGX/DBA combinations increase the compliance and effectiveness of therapy. The creation of therapy algorithms of mild asthma will be an important step to optimize medical care and to attract the attention of doctors to the problem of easy asthma. The goal of recommendations. To provide clinicians with based on the results of controlled clinical trials algorithms for mild asthma treatment.

Antibiotic Drug Levels

1995 ◽  
Vol 16 (11) ◽  
pp. 438-439
Author(s):  
Michael G. Rosenberg
Keyword(s):  
Clinical Trials ◽  
Antimicrobial Agents ◽  
Therapeutic Equivalence ◽  
Relative Toxicity ◽  
Antibiotic Regimen ◽  
Controlled Clinical Trials ◽  
The Past ◽  
Antibiotic Drug ◽  
New Compounds ◽  
Selection Of

In the past, efficacy, as defined by controlled clinical trials, was the primary factor in the selection of a particular antibiotic regimen. Today, as the number of antimicrobial agents approved for clinical use has grown almost exponentially, efficacy rarely is emphasized in published clinical trials. More commonly they demonstrate therapeutic equivalence rather than superiority of new compounds to previously accepted regimens. For this reason, the two criteria that now factor most prominently into the selection of equally effective antibiotics are relative toxicity and cost. Three major classes of antibiotics used throughout the world in the treatment of serious pediatric infectious diseases are chloramphenicol (CAP) and its derivatives, aminoglycosides (AGs), and vancomycin and related glycopeptides.

Systematic Planning of Clinical Documentation

1996 ◽  
Vol 35 (01) ◽  
pp. 25-34 ◽  
Author(s):  
R. Haux ◽  
F. Leiner
Keyword(s):  
Clinical Trials ◽  
Medical Care ◽  
Study Protocol ◽  
Clinical Documentation ◽  
Controlled Clinical Trials ◽  
Documentation System ◽  
Potential Part ◽  
Systematic Planning ◽  
The Individual ◽  
Design Options

AbstractAll information obtained from a patient in the course of medical care is a potential part of clinical documentation. The documentation usually serves a number of different purposes. The task of a documentation system is to fulfil these purposes in a methodically correct manner and as economically as possible. This requires that the properties of the documentation system be planned systematically with a view to the goals pursued. To support systematic planning, a “documentation protocol” is proposed analogous to the “study protocol” used for controlled clinical trials. The individual sections of the proposed documentation protocol are described and the design options which exist in the corresponding planning phases are pointed out. Experience gained by the application of the documentation protocol is discussed.

Antibiotic Drug Levels

1995 ◽  
Vol 16 (10) ◽  
pp. 397-398
Author(s):  
Michael G. Rosenberg
Keyword(s):  
Clinical Trials ◽  
Antimicrobial Agents ◽  
Therapeutic Equivalence ◽  
Relative Toxicity ◽  
Antibiotic Regimen ◽  
Controlled Clinical Trials ◽  
The Past ◽  
Antibiotic Drug ◽  
New Compounds ◽  
Selection Of

In the past, efficacy, as defined by controlled clinical trials, was the primary factor in the selection of a particular antibiotic regimen. Today, as the number of antimicrobial agents approved for clinical use has grown almost exponentially, efficacy rarely is emphasized in published clinical trials. More commonly they demonstrate therapeutic equivalence rather than superiority of new compounds to previously accepted regimens. For this reason, the two criteria that now factor most prominently into the selection of equally effective antibiotics are relative toxicity and cost. Three major classes of antibiotics used throughout the world in the treatment of serious pediatric infectious diseases are chloramphenicol (CAP) and its derivatives, aminoglycosides (AGs), and vancomycin and related glycopeptides.

scholarly journals Current and Future Drug and Device Therapies for Pediatric Heart Failure Patients: Potential Lessons from Adult Trials

Children ◽  
2021 ◽  
Vol 8 (5) ◽  
pp. 322
Author(s):  
Bibhuti B. Das ◽  
William B. Moskowitz ◽  
Javed Butler
Keyword(s):  
Heart Failure ◽  
Clinical Trials ◽  
Systolic Function ◽  
Lessons Learned ◽  
Pathophysiological Mechanism ◽  
Controlled Clinical Trials ◽  
Pharmacokinetics And Pharmacodynamics ◽  
Future Drug ◽  
Pediatric Heart Failure ◽  
Selection Of

This review discusses the potential drug and device therapies for pediatric heart failure (HF) due to reduced systolic function. It is important to realize that most drugs that are used in pediatric HF are extrapolated from adult cardiology practices or consensus guidelines based on expert opinion rather than on evidence from controlled clinical trials. It is difficult to conclude whether the drugs that are well established in adult HF trials are also beneficial for children because of tremendous heterogeneity in the mechanism of HF in children and variations in the pharmacokinetics and pharmacodynamics of drugs from birth to adolescence. The lessons learned from adult trials can guide pediatric cardiologists to design clinical trials of the newer drugs that are in the pipeline to study their efficacy and safety in children with HF. This paper’s focus is that the reader should specifically think through the pathophysiological mechanism of HF and the mode of action of drugs for the selection of appropriate pharmacotherapy. We review the drug and device trials in adults with HF to highlight the knowledge gap that exists in the pediatric HF population.

scholarly journals Controversial Use of Antibiotics in Patient with Sars-Cov-2

2021 ◽  
Vol 01 (06) ◽  
Author(s):  
Carlos Mauricio Vergara Lobo ◽  
Keyword(s):  
Clinical Trials ◽  
Functional Role ◽  
Rna Viruses ◽  
Controlled Clinical Trials ◽  
Respiratory Illnesses ◽  
New Type ◽  
The Common ◽  
Search And Selection ◽  
Bacterial Superinfection ◽  
Selection Of

Background: The SARS-CoV-2 coronavirus is a new type of coronavirus that can affect people and the disease it causes is called COVID-19. Coronaviruses are enveloped RNA viruses that cause respiratory illnesses of varying severity, from the common cold to deadly pneumonia. The WHO first learned of the existence of this new virus on December 31, 2019, when it was informed of a group of cases of "viral pneumonia" that had been declared in Wuhan. Methodology: A narrative review was carried out through various databases from January 2020 to June 2021; the search and selection of articles was carried out in journals indexed in English. The following keywords were used: Coronavirus, Sars-Cov 2, Covid 19, ARDS in Covid 19, Antibiotics Associated with Sars-Cov 2 Results: There are no controlled clinical trials evaluating the use of empirical antimicrobials in patients with COVID-19 or other coronaviruses. Therefore, the recommendations are based on extrapolation of data from other viral pneumonias that may suffer from bacterial superinfection, particularly viral pneumonias due to influenza. Conclusions: The present review seeks to clarify the functional role that antimicrobials have with respect to infection by sars-cov 2 (COVID-19), in which circumstances they are necessary to use them and which do not merit it.

Clinical trials screening: An opportunity to increase medical care access

2001 ◽  
Vol 120 (5) ◽  
pp. A410-A410
Author(s):  
T KOVASC ◽  
R ALTMAN ◽  
R JUTABHA ◽  
G OHNING
Keyword(s):  
Clinical Trials ◽  
Medical Care ◽  
Care Access

A rejoinder to "Psychotherapy research ethics: Continuing the debate on controlled clinical trials."

1987 ◽  
Vol 42 (12) ◽  
pp. 1132-1133
Author(s):  
Stanley D. Imber ◽  
Lawrence M. Glanz ◽  
Irene Elkin ◽  
Stuart M. Sotsky ◽  
Jenny L. Boyer ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Research Ethics ◽  
Psychotherapy Research ◽  
Controlled Clinical Trials

A Multivariate Approach to Analyze Ordinal Data Collected in Clinical Trials of Analgesic Agents

1979 ◽  
Vol 18 (03) ◽  
pp. 175-179
Author(s):  
E. Mabubini ◽  
M. Rainisio ◽  
V. Mandelli
Keyword(s):  
Clinical Trials ◽  
Multivariate Analysis ◽  
Analgesic Effect ◽  
Ordinal Data ◽  
Ordinal Scale ◽  
Multivariate Approach ◽  
Controlled Clinical Trials ◽  
Second Stage ◽  
Analgesic Agents ◽  
Relevant Factors

After pointing out the drawbacks of the approach commonly used to analyze the data collected in controlled clinical trials carried out to evaluate the analgesic effect of potential agents, the authors suggest a procedure suitable for analyzing data coded according to an ordinal scale. In the first stage a multivariate analysis is carried out on the codec! data and the projection of each result in the space of the most relevant factors is obtained. In the second stage the whole set of these values is processed by distribution-free tests. The procedure has been applied to data previously published by VENTAITBIDDA et al. [18].

Sign in / Sign up

Export Citation Format

Share Document